Abstract 910P
Background
Parotid mucoepidermoid carcinoma (P-MEC) is a major histopathological subtype of salivary gland cancer, characterized by heterogeneity and complexity. Traditional clinical models and treatment plans are limited in providing personalized treatment recommendations and clinical management. This study aims to develop a machine learning-based prognostic model to improve survival rate prediction accuracy for P-MEC patients.
Methods
We used SEER database data (2004-2015) for 882 postoperative P-MEC patients. Single-factor Cox regression and four machine learning algorithms (Random Forest, LASSO, XGBoost, Best Subset Regression) were employed for variable selection and importance evaluation. The optimal variable selection model was determined using stepwise backward regression, AIC, and AUC. Bootstrap resampling was applied for internal validation.The model's prediction accuracy was assessed through C-index, ROC curve, and calibration curve. The clinical utility of the model was evaluated via DCA.
Results
The 3-, 5-, and 10-year OS rates for postoperative P-MEC patients were 0.887, 0.841, and 0.753. XGBoost, BSR, and LASSO demonstrated good predictive performance in variable selection and identified 7 independent prognostic factors: age, pathological grade, T stage, N stage, radiation therapy, chemotherapy, and marital status. A nomogram was developed based on the identified predictive variables. Internal validation with 1000 bootstrap resamples yielded consistent results for C-index (3-year, 0.841, 95%CI=0.839-0.844; 5-year, 0.842, 95%CI=0.840-0.845) and AUC (3-year, 0.858, 95%CI=0.856-0.860; 5-year, 0.872, 95%CI=0.870-0.875). The calibration plot indicated good prediction fit.
Conclusions
This study identified age, pathological grade, T stage, N stage, radiation therapy, chemotherapy, and marital status as independent prognostic factors in postoperative P-MEC patients. Machine learning algorithms outperformed traditional analysis methods in variable selection, predictive performance, and variable importance visualization. The developed machine learning-based nomogram offers high accuracy, robust calibration, and clinical application value for postoperative P-MEC patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
932P - Survival in patients with relapsed/metastatic head and neck squamous cell carcinoma (HNSCC) treated with pembrolizumab or cetuximab-based therapy: A real-worlddata study with the TriNetX platform
Presenter: Lisardo Ugidos De La Varga
Session: Poster session 12
934P - Antitumor activity and safety profile of camrelizumab plus docetaxel, cisplatin, and capecitabine for induction therapy in advanced stage hypopharyngeal carcinoma
Presenter: Hongli Gong
Session: Poster session 12
938P - Nivolumab (nivo) in recurrent and/or metastatic squamous cell carcinoma of head and neck (R/M SCCHN): real-world effectiveness, quality of life (QoL) of patients and their caregivers in France (ProNiHN study)
Presenter: Christophe Le Tourneau
Session: Poster session 12
939P - Efficacy and safety of a novel anti-EGFR ADC MRG003 in recurrent or metastatic squamous cell carcinoma of the head and neck patients
Presenter: Liqiong Xue
Session: Poster session 12
940P - Salvage chemotherapy after progression on nivolumab in patients with squamous cell carcinoma of the head and neck included in the phase II TOPNIVO trial
Presenter: Khalil Saleh
Session: Poster session 12
941P - Risk factors for progressive disease after immune checkpoint inhibitors (ICIs) in advanced head and neck squamous cell carcinoma (HNSCC): Who might not be candidate for ICI?
Presenter: Seo Yoon Jang
Session: Poster session 12